Emgality and Oedema - a phase IV clinical study of FDA data

Summary:

Oedema is reported as a side effect among people who take Emgality (galcanezumab-gnlm), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Carbidopa And Levodopa, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Oedema when taking Emgality. It is created by eHealthMe based on reports of 24,623 people who have side effects when taking Emgality from the FDA, and is updated regularly.

What is Emgality?

Emgality has active ingredients of galcanezumab-gnlm. eHealthMe is studying from 24,702 Emgality users. Check the latest studies of Emgality.

What is Oedema?

Oedema (fluid collection in tissue) is found to be associated with 2,200 drugs and 2,311 conditions by eHealthMe. Check the latest studies of Oedema.

On Jul, 20, 2026

24,623 people reported to have side effects when taking Emgality.
Among them, 14 people (0.06%) have Oedema.

Among these 14 people:

How long have people been on Emgality when they have Oedema? *

What is the gender of people who have Oedema when taking Emgality? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Oedema when taking Emgality? *

What are other drugs people take besides Emgality? *

Hydrocodone: 5 people, 35.71%
Carafate: 5 people, 35.71%
Fluphenazine: 5 people, 35.71%
Nurtec Odt: 5 people, 35.71%
Ondansetron: 5 people, 35.71%
Clopidogrel: 5 people, 35.71%
Vitamin D2: 5 people, 35.71%
Oxycontin: 5 people, 35.71%
Pantoprazole: 5 people, 35.71%
Carbidopa And Levodopa: 5 people, 35.71%

What are other side effects people have besides Oedema? *

Fatigue (feeling of tiredness): 8 people, 57.14%
Hypoaesthesia (reduced sense of touch or sensation): 7 people, 50.00%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 5 people, 35.71%
Infusion Site Erythema (reddening of the skin at infusion site): 5 people, 35.71%
Back Pain: 5 people, 35.71%
Migraine (headache): 5 people, 35.71%
Nausea (feeling of having an urge to vomit): 5 people, 35.71%
Infusion Site Pain: 5 people, 35.71%
Thyroid Cancer Recurrent (reoccurs thyroid cancer): 5 people, 35.71%
Fall: 5 people, 35.71%

What are the existing conditions these people have? *

Migraine (headache): 5 people, 35.71%
Immunodeficiency Common Variable: 5 people, 35.71%
Post-Traumatic Headache: 1 person, 7.14%
Migraine With Aura (headache with vision weakness): 1 person, 7.14%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Emgality and have Oedema?

- Check whether Oedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Emgality:

Emgality (24,702 reports)

Oedema treatments and more:

Oedema (78,747 reports)

Browse all side effects of Emgality:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Oedema:

Oedema (2,199 drugs)

Browse all the conditions that are associated with Oedema:

Oedema (2,311 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on galcanezumab-gnlm (the active ingredients of Emgality) and Emgality (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.